CLINICAL AND STATISTICAL EVALUATION OF THE IMPACT OF PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY (PIPAC) ON QUALITY OF LIFE IN PATIENTS WITH PERITONEAL CARCINOMATOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY
Keywords:
To adapt the present manuscript to the real-world clinical cohort provided and to evaluate the clinical profile of patients undergoing PIPAC, with particular emphasis on symptom burden, treatment feasibility, laboratory dynamics, and quality-of-life indicators before and after treatment.Abstract
Background: Quality of Life (QoL) has become a key endpoint in modern oncology, particularly in patients with advanced ovarian cancer and peritoneal carcinomatosis. In such patients, the goal of treatment is not always curative but rather focused on disease control, symptom reduction, and preservation of functional capacity. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been proposed as a minimally invasive locoregional approach aimed at improving intraperitoneal drug delivery while reducing systemic toxicity.
References
Tempfer C.B., Celik I., Solass W. ва ғ. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer: A phase II study // Gynecol Oncol. - 2015. - Vol. 137, №2. - P. 223-228.
Alyami M., Hübner M., Grass F. ва ғ. Pressurized intraperitoneal aerosol chemotherapy: Rationale, evidence, and future directions // Lancet Oncol. - 2019. - Vol. 20, №7. - P. e368-e377.
Piso P., Dahlke M.H., Loss M. ва ғ. Treatment of peritoneal carcinomatosis using PIPAC // Ann Surg Oncol. - 2018. - Vol. 25, №2. - P. 412-419.
Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N. ва ғ. NCCN Clinical Practice Guidelines in Oncology: Ovarian cancer // J Natl Compr Canc Netw. – 2021. - Vol. 19, №2. - P. 191-226.
Lheureux S., Gourley C., Vergote I. ва ғ. Epithelial ovarian cancer // Lancet. - 2019. - Vol. 393, №10177. - P. 1240-1253.
Bray F., Ferlay J., Soerjomataram I. ва ғ. Global cancer statistics 2020 // CA Cancer J Clin. - 2021. - Vol. 71, №3. - P. 209-249.
van Driel W.J., Koole S.N., Sikorska K. ва ғ. Hyperthermic intraperitoneal chemotherapy in ovarian cancer // N Engl J Med. - 2018. - Vol. 378, №3. - P. 230-240.
Hübner M., Teixeira Farinha H., Grass F. ва ғ. Feasibility and safety of PIPAC: A systematic review // Eur J Surg Oncol. - 2017. - Vol. 43, №6. - P. 1102-1109.
Tempfer C.B., Rezniczek G.A., Ende P. ва ғ. Pressurized intraperitoneal aerosol chemotherapy in clinical practice // Oncol Res Treat. - 2018. - Vol. 41, №3. - P. 116-121.
Coccolini F., Gheza F., Lotti M. ва ғ. Peritoneal carcinomatosis: Review of pathophysiology and management // World J Gastroenterol. - 2013. - Vol. 19, №41. - P. 6979-6994.
Aaronson N.K., Ahmedzai S., Bergman B. ва ғ. The EORTC QLQ-C30: A quality-of-life instrument // J Natl Cancer Inst. - 1993. - Vol. 85, №5. - P. 365-376.
Eisenhauer E.A., Therasse P., Bogaerts J. ва ғ. New response evaluation criteria in solid tumours (RECIST) // Eur J Cancer. - 2009. - Vol. 45, №2. - P. 228-247.
Sugarbaker P.H. Peritoneal carcinomatosis: Principles of management // Ann Surg. - 1995. - Vol. 221, №1. - P. 29-42.
Esquis P., Consolo D., Magnin G. ва ғ. High-pressure aerosol chemotherapy enhances drug penetration // Ann Surg Oncol. - 2007. - Vol. 14, №2. - P. 546-554.
Tempfer C.B., Winnekendonk G., Solass W. ва ғ. PIPAC for peritoneal metastasis: Systematic review // Gynecol Oncol. - 2014. - Vol. 132, №3. - P. 736-742.
